Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6767065 | 0.84 | KDM4E (0.32) | KDM4EALDH1A1HPGDHTR2BHTR2A | |
| SCHEMBL6766736 | 0.80 | KDM4E (0.30) | KDM4EALDH1A1HPGDHTTATM | |
| SCHEMBL6767081 | 0.69 | KDM4E (0.31) | KDM4EALDH1A1HTTATM | |
| SCHEMBL6315032 | 0.63 | KDM4E (0.35) | KDM4EALDH1A1HTTATM | |
| SCHEMBL6306457 | 0.63 | KDM4E (0.35) | KDM4EALDH1A1HTTATM | |
| SCHEMBL6768175 | 0.63 | KDM4E (0.38) | KDM4EALDH1A1HPGDHTTATM | |
| SCHEMBL6308630 | 0.63 | KDM4E (0.35) | KDM4EALDH1A1HTTATM | |
| SCHEMBL6766768 | 0.63 | KDM4E (0.32) | KDM4EALDH1A1HTTATM | |
| SCHEMBL6766921 | 0.63 | KDM4E (0.33) | KDM4EALDH1A1HPGDHTTATM | |
| SCHEMBL6767205 | 0.62 | ELANE (0.41) | KDM4EALDH1A1HPGDATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686389-B2 | KIDNEY DISEASE, ORGAN TRANSPLANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-02-03 | — | — | US | disclosed |
| US-20020156296-A1 | 2,3-dihydrobenzofuran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-10-24 | — | — | US | disclosed |
| US-6403639-B1 | POTENT CYTOPROTECTIVE AGENT WHICH INHIBITS LIPID-PEROXIDATION FOR PREVENTION AND TREATMENT OF VARIOUS RENAL DISEASES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-06-11 | — | — | US | disclosed |
| EP-0995437-A1 | 2,3-DIHYDROBENZOFURAN DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156296-A1 | 2,3-dihydrobenzofuran derivatives | CBR1, CYP2F1, NDUFAF2 | KDM4E 4048/4885ALDH1A1 7/4885HPGD 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.